Diabetes, Vol 49, Issue 7 1224-1230, Copyright © 2000 by American Diabetes Association
Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and troglitazone reverse lactation-induced downregulation of the uncoupling protein-3 gene
N Pedraza, G Solanes, MC Carmona, R Iglesias, O Vinas, T Mampel, M Vazquez, M Giralt and F Villarroya
Department of Biochemistry and Molecular Biology, University of Barcelona, Spain.
The expression of uncoupling protein (UCP)-3 mRNA in skeletal muscle is
dramatically reduced during lactation in mice. The reduction in UCP-3 mRNA
levels lowers the amount of the UCP-3 protein in skeletal muscle
mitochondria during lactation. Spontaneous or abrupt weaning reverses the
downregulation of the UCP-3 mRNA but not the reduction in UCP-3 protein
levels. In lactating and virgin mice, however, fasting increases UCP-3 mRNA
levels. Changes in UCP-3 mRNA occur in parallel with modifications in the
levels of free fatty acids, which are reduced in lactation and are
upregulated due to weaning or fasting. Modifications in the energy
nutritional stress of lactating dams achieved by manipulating litter sizes
do not influence UCP-3 mRNA levels in skeletal muscle. Conversely, when
mice are fed a high-fat diet after parturition, the downregulation of UCP-3
mRNA and UCP-3 protein levels due to lactation is partially reversed, as is
the reduction in serum free fatty acid levels. Treatment of lactating mice
with a single injection of bezafibrate, an activator of the peroxisome
proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal
muscle to levels similar to those in virgin mice.
4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a
specific ligand of the PPAR-alpha subtype, causes the most dramatic
increase in UCP-3 mRNA, whereas troglitazone, a specific activator of
PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal
muscle of lactating mice. However, in virgin mice, bezafibrate and
WY-14,643 do not significantly affect UCP-3 mRNA expression, whereas
troglitazone is at least as effective as it is in lactating dams. It is
proposed that the UCP-3 gene is regulated in skeletal muscle during
lactation in response to changes in circulating free fatty acids by
mechanisms involving activation of PPARs. The impaired expression of the
UCP-3 gene is consistent with the involvement of UCP-3 gene regulation in
the reduction of the use of fatty acids as fuel by the skeletal muscle and
in impaired adaptative thermogenesis, both of which are major metabolic
adaptations that occur during lactation.